Nura, Inc. (Seattle, USA) was founded in August 2003 for the purpose of discovering and developing pharmaceuticals for the treatment of neurodegenerative diseases, such as Parkinson's and Alzheimers's diseases, and behavioral disorders, such as depression, anxiety, schizophrenia, obesity and addiction. Nura was acquired by Omeros as of September 7, 2006.